Articles from Paragonix Technologies, Inc.

Paragonix Technologies, Inc., a leader in organ preservation technology, and Vanderbilt Health, one of the oldest and largest kidney transplant programs in the country, are proud to announce the successful transplantation of a donor kidney using the Paragonix KidneyVault™ Renal Perfusion System. The FDA-cleared portable hypothermic perfusion technology is designed to preserve and transport donor kidneys. Vanderbilt is the first in Tennessee, and one of the first in the entire Southeast to use this innovative system for kidney transport.

Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of FDA-cleared and CE marked controlled hypothermic preservation devices and transplant services. These presentations compare and analyze post-transplant outcomes of patients, presented by a multi-center panel of clinical investigators representing the GUARDIAN Clinical Registries at the 45th ISHLT Annual Meeting and Scientific Sessions, located at the Hynes Convention Center in Boston, MA from April 27-30, 2025.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, announces the annual release of the latest GUARDIAN-Heart Clinical Registry report, shared earlier today at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease. Notably, the unprecedented study represents the first time any medical device technology has ever demonstrated statistically significant improvements in 2-year survival following heart transplantation.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard®, in the largest real-world multi-center study presented at the 44th ISHLT Annual Meeting and Scientific Sessions – one of the largest international conferences focused on advanced treatment for end-stage heart and lung disease. The study compares conventional ice storage to the Paragonix LUNGguard system. The analysis revealed that advanced lung preservation technology with the Paragonix LUNGguard favorably influences post-transplant outcomes, including reductions in primary graft dysfunction, the use of invasive MCS interventions, and improvement in renal function.

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and procurement services, announces the full commercial launch of its next-generation transport device, the BAROguard™ Donor Lung Preservation System. After an overwhelmingly positive response and demand during its limited market release, the technology is now available to transplant centers and Organ Procurement Organizations across the United States.

Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of controlled hypothermic preservation and clinical services. These presentations compare and analyze post-transplant outcomes of patients, presented by a multi-center panel of clinical investigators representing the GUARDIAN Clinical Registries at the 44th ISHLT Annual Meeting and Scientific Sessions, located at the Prague Congress Center in Prague, Czech Republic from April 10-13, 2024.

Paragonix Technologies, Inc. achieves a historic milestone in Puerto Rico with the first-ever utilization of its advanced liver preservation technology, the LIVERguard™ Donor Liver Preservation System, which preserved, monitored, and tracked a donor liver throughout its extended trip to a transplant center in Florida. The recovery was managed by the expert staff of LifeLink of Puerto Rico, a non-profit Organ Procurement Organization (OPO). LifeLink of Puerto Rico works closely with donor hospitals throughout the territory to facilitate organ donation and save the lives of patients in need of lifesaving transplantation. When a potential recipient for a donated liver cannot be identified within Puerto Rico, Paragonix LIVERguard technology will allow the donated liver to reach patients awaiting of a liver transplant at transplant centers on the U.S. mainland.

Paragonix Technologies, Inc., a leading organ transplant company, announced today the publication of groundbreaking research from a clinical study on patient outcomes following heart transplant surgery. The multi-center study compared the use of Paragonix SherpaPak® Cardiac Transport System, the leading FDA-cleared and CE-marked donor heart preservation and transport device, to the use of conventional cold storage using ice in the preservation of donor hearts. Published in The American Society for Artificial Internal Organs (ASAIO), the study utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database dedicated to donor heart preservation, to analyze post-transplant outcomes and the impact on organ preservation methods on transplant patient health.

Paragonix Technologies, Inc., a leading organ transplant company, announces a milestone achievement with Massachusetts General Hospital (Boston, MA) successfully accessing a donor heart over a total of 2,506 nautical miles away using the Paragonix SherpaPak® Cardiac Transport System. Beginning in Juneau, Alaska, and ending in Boston, Massachusetts, the procurement distance beats previous records in distance to safely deliver a donor heart to a recipient.

Paragonix Technologies, Inc., a leading organ transplant company, announces that the latest clinical report of over 1,000 transplant patients studied in the GUARDIAN-Heart Registry was presented at the 2023 ISHLT Annual Meeting & Scientific Sessions. GUARDIAN clinical investigators and 21 independent transplant centers presented extensive findings in over 20 presentations throughout the conference, detailing the impact of advanced donor heart preservation and the clinical benefits that transplant recipients experienced with the use of the Paragonix SherpaPak Cardiac Transport System.

Paragonix Technologies, Inc., the leading organ transplant company, presented impactful clinical data on the use of its Advanced Organ Preservation system, LUNGguard™, in a study presented at this year’s ISHLT Annual Meeting & Scientific Sessions. The study compares conventional ice-cold storage to the Paragonix LUNGguard™ system, using real-world multi-center data collected from the GUARDIAN-Lung Registry. The analysis illustrates that advanced lung preservation technology favorably influences post-transplant outcomes, including a 24% reduction in 1-year readmission rates (p=0.018). 1 One-year readmission rates can be an indication of potential costly post-transplant complications, making the results of the study an important development for lung transplant centers.

Paragonix Technologies, Inc., the leader in organ preservation technology and research, has presented new groundbreaking data on the clinical impact of using Paragonix SherpaPak Cardiac Transport System to preserve donor hearts from extended criteria donors. An extended criteria donor is a term used in organ transplantation to describe a donor who may not meet the standard criteria of organ donation but is still considered suitable for donation. The use of extended criteria donor organs can increase the availability of transplantable organs but has also historically carried a higher risk of complications for the recipient. This recent study compared the use of traditional ice-cold storage to the Paragonix SherpaPak® Cardiac Transport System, the leading FDA-cleared and CE-marked medical device for donor heart preservation, to measure the post-transplant outcomes of recipients who received an extended criteria donor heart. In the recipient group which utilized the Paragonix SherpaPak for organ preservation, the analysis found a significant reduction of 45% in Primary Graft Dysfunction (PGD). The results also showed a reduction of 55% in Severe PGD, a more severe complication shown to impact long-term survival of heart transplant recipients.

Paragonix Technologies, Inc., a leading organ transplant company, is dedicated to advancing the science of modern transplantation by conducting novel research powered by the GUARDIAN registries - the largest clinical databases specifically focused on the preservation of donor organs during transport. Participating investigators will present research on a variety of factors - including organ preservation, transportation, and characteristics of both donors and recipients - at the 2023 International Society for Heart and Lung Transplantation 43rd Annual Meeting and Scientific Sessions, held in late April at the Colorado Conference Center in Denver, CO.

Paragonix Technologies, Inc., a leading organ transplant company, today announced that it has secured $24 million in Series B funding, led by Signet Healthcare Partners. This growth investment will bolster Paragonix Technologies’ commercial footprint, including its ongoing extension of clinical service offerings and inventory expansion, and will enable the Company to further advance transplant innovations.

Paragonix Technologies, Inc., a leading organ transplant company, announces new research from a multi-center study on transplant patient outcomes following heart transplant surgery. The study compared the use of the Paragonix SherpaPak® Cardiac Transport System, an FDA-cleared and CE-marked donor heart transport and preservation device, to the use of conventional ice storage for LVAD patients undergoing heart transplantation. Presented at the 2023 American Association of Cardiology Annual Meeting (ACC23) on March 6, the study focused on short term post-transplant outcomes, and utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database specifically dedicated to heart preservation.

Paragonix Technologies, Inc., a leading organ preservation provider, announced today a pioneering lung transplantation case in which donor lungs procured overnight were preserved with the LUNGguard Donor Lung Preservation System, allowing for next day transplant surgery led by Prof. Dr. Laurens Ceulemans at UZ Leuven in Belgium. UZ Leuven Hospital, one of the most innovative and respected transplant centers in Europe, recently completed this landmark case, also marking the first use of the LUNGguard System in a pediatric lung transplant case anywhere in the world.

Paragonix Technologies, Inc. achieves a historic milestone in Hawaii with the first-ever utilization of its advanced lung preservation technology, the Paragonix LUNGguard™ system, which protected, monitored and geo-tracked a pair of donor lungs throughout its lengthy voyage to California. The donor organ recovery was managed by the expert staff of Legacy of Life Hawaii, a nonprofit Organ Procurement Organization (OPO) and the only organization in Hawaii federally designated to recover organs and tissue for transplant. Legacy of Life Hawaii works closely with island hospitals to procure and place donor organs for patients in need.

Paragonix Technologies, Inc., a leader in organ preservation technology and research, has announced the publication of a groundbreaking organ transplant study in the American Society for Artificial Internal Organs (ASAIO) Journal. This new study utilizes real-world clinical data to contrast two preservation methods: the Paragonix SherpaPak® Cardiac Transport System (PGNX), and the historic method of organ transport, ice cold storage (ICE). The study illustrates the favorable post-operative impact that advanced preservation technology may have on hospital costs and patient outcomes after heart transplant procedures.

Paragonix Technologies, Inc., a leader in Advanced Organ Preservation (AOP) technology, has announced the launch of its new VantagePoint™ Organ Tracking Technology to pioneer a new era of continuous oversight and real-time visibility for donor organs in transit. Designed to meet the rising standards of transparency and accountability in donor organ transportation, this technology will improve the digital tracking capabilities provided by the Paragonix App, the free-to-download software, paired with all Paragonix Advanced Organ Preservation (AOP) Devices to meet the evolving needs of organ transplant professionals.

Paragonix Technologies, Inc. is announcing a major milestone of preserving over 2,000 donor organs, providing transplant centers Advanced Organ Preservation (AOPT) technology and a nationwide clinical support network. Each of these technologies utilize first-of-its-kind preservation methods and have proven to be a major advancement over the current ice and cooler practice still used today. Paragonix devices combine clinically-proven, stable, hypothermic preservation technology with an extensive clinical support network, supplemented by innovative digital tools for complete control over organ tracking, monitoring, and reporting.1

Paragonix Technologies, Inc., a leading organ preservation provider, announced expanded adoption of their LIVERguard Donor Liver Preservation System at the 2022 American Transplant Congress in Boston, Massachusetts. Since the commercial introduction of the LIVERguard system in January 2022, the advanced donor organ preservation system has been utilized at 8 U.S. transplant centers, including UF Health Shands, one of the largest liver transplant centers in the world. Additionally, Paragonix has been partnering with numerous Organ Procurement Organizations in order to provide more access to this unique hypothermic preservation technology.

Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking research from a multi-center study on one-year transplant patient outcomes following heart transplant surgery. The study compared the use of the Paragonix SherpaPak Cardiac Transport System, an FDA-cleared and CE-marked donor heart transport and preservation device, to the use of conventional cold storage using ice in the preservation of donor hearts destined for transplantation. Presented at the 2022 Annual Meeting of the International Society for Heart and Lung Transplantation on April 27, the study focused on post-transplant outcomes and survival, and utilized data collected by the GUARDIAN-Heart Registry, the world’s largest clinical database specifically dedicated to heart preservation.

Paragonix Technologies, Inc., a leading organ preservation provider, is presenting new research on a variety of organ preservation, transportation and clinical data collection topics. These include data presentations comparing the impact of different preservation methods based on patient outcomes and transplant survival analysis, at the 2022 ISHLT 42nd Annual Meeting and Scientific Sessions conference held at the Hynes Convention Center in Boston, MA.

Paragonix Technologies, Inc. is announcing the release of the recently developed Paragonix Web Portal, an accessible support platform that connects with the Paragonix App and donor organ preservation devices to provide transplant teams the ability to digitally participate in live sessions or review historical cases and clinical case data. For the first time, Paragonix App users will have access to all historical case information specific to their account, with the ability to access the data in aggregate in order to make decisions on how to optimize their organ procurement procedures and protocols.

Paragonix Technologies, Inc. is announcing a major milestone of 1,000 preserved donor heart transports since it began clinical use in 2018, with its flagship product, the Paragonix SherpaPak® Cardiac Transport System (CTS). The Paragonix SherpaPak CTS is the leading FDA cleared and CE marked medical device for heart preservation and transport. Four of the top five largest heart transplant programs in the US and 45 programs globally now trust the Paragonix SherpaPak System to preserve and transport critical donor hearts to their recipient donors.

Paragonix Technologies, Inc. today announces that the University of Florida Health (UF Health) is the first to enroll a pediatric heart transplant recipient into the Company’s post-market registry, the Global Utilization And Registry Database for Improved preservAtion of donor HEARTs (GUARDIAN-HEART) Pediatric Registry. The GUARDIAN-HEART Pediatric research initiative joins two other prominent research efforts from Paragonix, the adult GUARDIAN-HEART registry for donor heart preservation and the GUARDIAN-LUNG registry for donor lung preservation, to work alongside clinical partners to collect real-world data on a missing piece of the organ donation and transplantation process: the impact of advanced preservation methods compared to standard methods.

Paragonix Technologies, Inc. today announces the launch of its clinical global registry, GUARDIAN-LUNG (Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs). The GUARDIAN-LUNG study is unlike any lung donation registry as it seeks to evaluate a missing piece of the organ donation process: the impact of methods and technologies used for lung preservation and transportation on the success of transplant surgery.